Group IIa

2 trials

Sponsors

Swedish Institute for Infectious Disease Control, Tanta University Hospital

Conditions

Acute aluminum phosphide toxicityHIV/AIDS

Phase 3

The Adjuvant Role of Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Patients

Active, not recruitingPACTR202408492665945

Tanta University HospitalAcute aluminum phosphide toxicity

Start: 2024-06-01Target: 135Updated: 2026-09-14

Unknown Phase

Active, not recruitingPACTR2010050002122368

Swedish Institute for Infectious Disease ControlHIV/AIDS

Start: 2010-05-26Target: 120Updated: 2026-09-14

Related Papers

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial

PLoS ONE2016-05-1820 citations

Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial

PLoS ONE2015-04-1543 citations